PMID- 26437977
OWN - NLM
STAT- MEDLINE
DCOM- 20170119
LR  - 20181023
IS  - 1130-0108 (Print)
IS  - 1130-0108 (Linking)
VI  - 107
IP  - 10
DP  - 2015 Oct
TI  - Efficacy and safety of simeprevir in combination with peginterferon and ribavirin 
      for patients with hepatitis C genotype 1 infection: a meta-analysis of randomized 
      trials.
PG  - 591-7
LID - 10.17235/reed.2015.3840/2015 [doi]
AB  - BACKGROUND AND AIM: A simeprevir (SMV)-based regimen has shown promising results 
      in treating chronic hepatitis C virus (HCV) infection. This meta-analysis aimed 
      to assess the efficacy and safety of simeprevir for treating HCV genotype 1 
      infection. METHODS: MEDLINE, EMBASE, and the Cochrane Central Register of 
      Controlled Trials were searched, along with the reference lists of retrieved 
      articles. The meta-analysis only included randomized controlled trials (RCTs) 
      that compared the efficacy and safety of addition of SMV to peginterferon 
      (PegIFN) and ribavirin (RBV) (triple regimen) with PegIFN/RBV alone (dual 
      regimen) in treating chronic HCV genotype 1 infection. RESULTS: A total of seven 
      RCTs involving 2,301 patients were included. The triple regimen had a higher 
      pooled sustained virologic response (SVR) rate [odds ratio (OR) = 4.57; 95% 
      confidence interval (CI): 3.34-6.27; p < 0.001)] and lower pooled relapse rate 
      [relative risk (RR) = 0.41; 95% CI: 0.33-0.50; p < 0.001] than the dual regimen 
      had. The pooled incidence of adverse events (AEs) was comparable between the two 
      regimens (RR = 1.01; 95% CI: 0.99-1.03; p = 0.339), whereas the incidence of 
      serious AEs in the triple regimen was lower (RR = 0.7; 95% CI: 0.50-0.98; p < 
      0.05). CONCLUSIONS: The meta-analysis demonstrates that the addition of SMV to 
      pegIFN and RBV is effective and well-tolerated in treating chronic HCV genotype 1 
      infection, with a low incidence of AEs.
FAU - Cui, Xianghua
AU  - Cui X
AD  - Liver Research Center, Being Friendship Hospital, Capital Medical Univers, China.
FAU - Kong, Yuanyuan
AU  - Kong Y
AD  - Clinical Epidemiology and EBM Unit, Being Friendship Hospital, Capital Medical 
      Univers, China.
FAU - Jia, Jidong
AU  - Jia J
AD  - Liver Research Center, Being Friendship Hospital, Capital Medical Univers, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - Spain
TA  - Rev Esp Enferm Dig
JT  - Revista espanola de enfermedades digestivas
JID - 9007566
RN  - 0 (Antiviral Agents)
RN  - 49717AWG6K (Ribavirin)
RN  - 9008-11-1 (Interferons)
RN  - 9WS5RD66HZ (Simeprevir)
SB  - IM
MH  - Antiviral Agents/*adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Genotype
MH  - Hepacivirus/*genetics
MH  - Hepatitis C, Chronic/*drug therapy/*virology
MH  - Humans
MH  - Interferons/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Ribavirin/*therapeutic use
MH  - Simeprevir/*adverse effects/*therapeutic use
EDAT- 2015/10/07 06:00
MHDA- 2017/01/20 06:00
CRDT- 2015/10/07 06:00
PHST- 2015/10/07 06:00 [entrez]
PHST- 2015/10/07 06:00 [pubmed]
PHST- 2017/01/20 06:00 [medline]
AID - 10.17235/reed.2015.3840/2015 [doi]
PST - ppublish
SO  - Rev Esp Enferm Dig. 2015 Oct;107(10):591-7. doi: 10.17235/reed.2015.3840/2015.